Interius BioTherapeutics
PHILADELPHIA, PA · Founded 2019 · CIK 0001807811 · Biotech · Acquired
In vivo CAR-T cell engineering platform using targeted viral vectors
interiustx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $118M
- 4 Form D · Jun 2024
- 28 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 4 granted · 36 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,575,000 | |
| Private capital raised | Form D · SEC | $43,625,657 | |
| Private capital raised | Form D · SEC | $21,451,331 | |
| Private capital raised | Form D · SEC | $51,432,536 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2810 | Edgewise Therapeutics | — | $120M |
| 2811 | Ensoma | — | $120M |
| 2812 | A2 Biotherapeutics | — | $119M |
| 2813 | Interius BioTherapeutics | — | $118M |
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
| 2816 | Mineralys Therapeutics, Inc. | — | $118M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bihua ChenDirector
- Lori ForrestExecutive Officer
- Saar GillExecutive Officer
- Philip JohnsonDirector · Executive Officer
- Philip Johnson, M.D.Director · Executive Officer
- Tomas KiselakDirector
- Benjamin LundDirector
- Dora MitchellExecutive Officer
- Leon MoulderDirector
- Leon Moulder, Jr.Director
- Bruce PeacockDirector · Executive Officer
Patents
- Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereofgranted
- Mutated Polypeptides, Compositions Comprising The Same, And Uses Thereofapplication
- Mutated Polypeptides, Compositions Comprising The Same, And Uses Thereofgranted
- Engineered Viral Particles And Uses Of The Sameapplication
- Ebola Pseudotyped Vectors And Methods Of Use Thereofapplication
- Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereofgranted
- Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereofapplication
- Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereofgranted
- Fusogenic Rhabdovirus Glycoproteins And Uses Thereofapplication
- Compositions And Methods For The Treatment Of Immunological Disordersapplication
- Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereofapplication
- Gene Editing Compositions Of Polypeptides And Nucleic Acids, And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.